Drug Database
DE

denosumab (RTPR045 / RTPR 045 / DenosteRel)

✓ Approved

Reliance Life Sciences Private Limited · TNFSF11 · 单克隆抗体

什么是 denosumab?

denosumab 是一种单克隆抗体,由Reliance Life Sciences Private Limited研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名RTPR045, RTPR 045, DenosteRel
公司Reliance Life Sciences Private Limited
药物类别单克隆抗体, 抗体
分子靶点TNFSF11
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

denosumab 作用于 1 个分子靶点:

TNFSF11TNF superfamily member 11 (ODF, CD254)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

denosumab 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Bone cancer✓ Approved
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

相关研究文献

PubMedJournal of medical case reports2026-11-19

Rapid progression of myocardial calcification in a patient presenting with hypercalcemia of unidentified etiology: a case report.

Hirai Shota S, Nishigaito Toshiya T, Mitsumoto Kensuke K, Mizumoto Aya A et al.

Myocardial calcification is an uncommon but clinically important finding that may result in severe cardiac dysfunction. It is generally classified as metastatic calcification triggered by an elevated serum calcium-phosphate product or dystrophic calcification occurring at sites of prior inflammatory or ischemic injury. There are few reports describing dynamic changes in myocardial calcification among patients with hypercalcemia. In addition, hypercalcemia with an unidentified cause has rarely been reported. We encountered a fatal case that developed both metastatic and dystrophic myocardial calcification. This case may contribute to a better understanding of the potential cardiac complications of severe hypercalcemia.Affiliations: Journal instruction requires a city and country for affiliations; however, these are missing in affiliation [2, 3]. Please verify if the provided city and country are correct and amend if necessary.All authors' affiliation addresses are Osaka, Japan. A 57-year-old Japanese woman with a history of asthma presented with nausea and fatigue. She had severe hypercalcemia with acute kidney injury and marked eosinophilia. Intact parathyroid hormone was suppressed (11 pg/mL), with normal parathyroid hormone-related protein and vitamin D metabolites. Fractional excretion of calcium was elevated to 12%. Imaging studies, bone marrow examination, and renal biopsy did not identify a definitive etiology. She was diagnosed with severe hypercalcemia of unidentified etiology complicated by acute kidney injury and eosinophilia. Despite intravenous fluids, calcitonin, and denosumab followed by hemodialysis, she developed progressive respiratory failure and circulatory collapse with myocardial injury and coronary microvascular dysfunction, and serial CT showed new myocardial calcification from day 9 with rapid diffuse progression. She died 22 days after admission despite extracorporeal circulatory support, and autopsy revealed extensive multi-organ calcification including the heart and lungs. Severe hypercalcemia of unidentified etiology can be complicated by extensive myocardial calcification. Ectopic calcification initially induced by hypercalcemia may have been influenced by inflammatory conditions such as eosinophilia. In addition, subsequent myocardial injury may accelerate dystrophic calcification. Clinicians should be aware of the risk of early and progressive cardiac involvement in patients with hypercalcemia, particularly in the presence of inflammatory conditions.

PMID 43053195
阅读全文 →
PubMedDrug safety2026-11-18

Medication-Related Osteonecrosis of the Jaw: An Unmasking Disproportionality Analysis of VigiBase, the WHO Spontaneous Reporting Database.

Arzenton Elena E, Marcianò Antonia A, Gozzi Federico F, Levita Domenico D et al.

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug reaction mainly associated with antiresorptive agents. High reporting frequency in spontaneous reporting databases for bisphosphonates and denosumab may mask potential signals for other drugs. The aim of the study was to describe reporting patterns and characteristics of MRONJ reports and to identify potential new safety signals using an unmasking disproportionality approach in VigiBase, the WHO global pharmacovigilance database. We conducted a retrospective disproportionality analysis of individual case safety reports (ICSRs) reporting osteonecrosis of the jaw up to May 22, 2025. Analysis was performed to describe demographic and clinical characteristics. Disproportionality analysis using reporting odds ratios (RORs) (95% confidence intervals) identified potential signals of disproportionate reporting (SDRs), according to a predefined statistical threshold. To reduce masking, analyses were repeated after excluding reports involving bisphosphonates or denosumab. Signals were prioritized based on regulatory labeling and absence of concomitant antiresorptive therapy. Among 32,570,624 ICSRs, 26,137 (0.08%) reported MRONJ, predominantly in females (65.0%) and patients aged ≥ 45 years (71.9%). Most cases were serious (93.2%) and commonly associated with oncologic or bone-related indications. After excluding bisphosphonates and denosumab, 1902 MRONJ reports remained. Unmasked analysis identified 82 SDRs (vs 34 before exclusion), with 43 prioritized signals largely involving antineoplastic and immunomodulating agents. Several drugs not currently labeled for MRONJ showed significant RORs independent of antiresorptive exposure. Beyond confirming established associations with bisphosphonates and denosumab, this unmasking pharmacovigilance approach identified potential new MRONJ safety signals. These findings are hypothesis-generating and warrant further validation through pharmacoepidemiologic studies.

PMID 43050138
阅读全文 →
PubMedEuropean geriatric medicine2026-11-17

Does the timing of postoperative denosumab administration affect fracture healing in intertrochanteric femoral fractures?

Do Min Uk MU, Kim Kyeong Baek KB, Lee Sang-Min SM, Shin Won Chul WC

Concerns remain regarding potential inhibitory effects of denosumab on fracture healing due to the suppression of bone turnover. This study aimed to determine whether the timing of postoperative denosumab administration affects healing outcomes in patients with intertrochanteric femoral fractures. This retrospective, observational study included 178 patients with surgically treated intertrochanteric femoral fractures. The patients were categorized according to the timing of denosumab administration as follows: within 1 week postoperatively (Group A, n = 82), at approximately 3 weeks (Group B, n = 48), and at approximately 6 weeks (Group C, n = 48). Fracture healing time, union rate, complications, and functional outcomes were compared between the groups. The association between fracture reduction quality and healing outcomes was evaluated in a sub-analysis. Mean fracture healing times were 18.6, 19.7, and 15.6 weeks in Groups A, B, and C, respectively, with no significant differences (p = 0.332). Union rates were not significantly different: 96.3%, 100%, and 100%, respectively (p = 0.168). Complication rates and functional outcomes did not differ between the groups. In contrast, acceptable or poor fracture reduction was significantly associated with non-union in the sub-analysis (p < 0.001). Compared to delayed administration, early postoperative administration of denosumab did not adversely affect fracture healing outcomes. Early administration of denosumab can be considered a safe and reasonable strategy to ensure the continuity of osteoporosis treatment. Achieving satisfactory fracture reduction may be more closely associated with successful fracture healing than the timing of denosumab initiation.

PMID 43040192
阅读全文 →
PubMedHormones (Athens, Greece)2026-11-17

Denosumab treatment of giant cell tumour of the sphenoid bone: case report and literature review.

Stempler Márk M, Sápi Zoltán Z, Nyilas Nóra N, Barsi Péter P et al.

Giant cell tumour of bone (GCTB) is a rare neoplasm that predominantly arises from the epiphysis of long bones. Surgical excision remains the gold standard for the management of GCTB. However, when GCTB originates from the sphenoid bone, complete surgical resection may be precluded due to the proximity of critical neural and vascular structures. The introduction of denosumab, a monoclonal antibody targeting RANKL, has provided an alternative therapeutic option for unresectable or surgically challenging cases. Given the rarity of sphenoid GCTB and the limited evidence regarding long-term medical management, detailed reports of prolonged treatment courses are essential to inform clinical practice. In May 2018, a 16-year-old female patient presented with severe headache, dizziness, vomiting, double vision, and right-sided retrobulbar pain. Magnetic resonance imaging (MRI) of the brain revealed a large sellar mass invading the right cavernous sinus. Endocrine assessment confirmed severe panhypopituitarism, for which appropriate hormone replacement therapy was initiated. Four months later, a follow-up MRI demonstrated significant tumour progression, prompting surgical intervention. Histopathological evaluation confirmed the diagnosis of GCTB. Postopera-tively, denosumab was commenced, resulting in a 40% volume regression within 5 months. Denosumab was continued until December 2021; In this period to December, disease stability was maintained. The therapy was subsequently discontinued. In July 2022, follow-up MRI revealed marked tumour progression, prompting the resumption of denosumab. The patient currently receives 120 mg every 4 weeks, with consequent significant tumour regression. We conducted a systematic literature search resulting in 14 case reports of sphenoid GCTB with short-medium-term denosumab treatment. Intracranial GCTBs, particularly those arising from the sphenoid bone, are rarely amenable to complete surgical resection, necessitating alternative therapeutic approaches. Overall, this case, to our knowledge, represents the longest reported duration of effective denosumab treatment for sphenoid GCTB to date, with sustained disease control over 7 years of therapy. It also demonstrates possible tumour progression in the event of cessation of denosumab therapy.

PMID 43040203
阅读全文 →
PubMedEndocrine2026-11-16

Hypercalcemia in patients with thyroid cancer: malignancy-related mechanisms, differential diagnosis, and management.

Mariano Jean Ferrante JF, Lazaretti-Castro Marise M, Ward Laura Sterian LS, Cunha Lucas Leite LL

Hypercalcemia associated with malignancy (HAM) represents a critical metabolic oncological emergency that signifies advanced systemic disease and carries prognostic significance. Although its prevalence in thyroid cancer is relatively low, affecting approximately 6.3% of patients in a historical terminal-stage cohort, it serves as a marker for aggressive tumor phenotypes and dedifferentiation. The pathophysiology is categorized into four recognized mechanisms, which may overlap: humoral hypercalcemia of malignancy (HHM) driven by systemic parathyroid hormone-related protein (PTHrP) secretion; local osteolytic hypercalcemia (LOH) resulting from direct bone destruction by metastatic cells; 1,25-dihydroxyvitamin D-mediated hypercalcemia; and the exceedingly rare ectopic secretion of authentic parathyroid hormone (PTH). Notably, anaplastic thyroid cancer (ATC) may present with a dual paraneoplastic syndrome involving concurrent systemic PTHrP secretion and a leukemoid reaction, whereas hypercalcemia in medullary thyroid cancer (MTC) often reflects benign parathyroid pathology associated with multiple endocrine neoplasia type 2 A (MEN2A), which is hypercalcemia in a patient with cancer rather than hypercalcemia caused by the malignancy. Diagnostic evaluation requires a systematic approach organized around PTH-dependent and PTH-independent hypercalcemia, including biochemical assessment of PTH, PTHrP, and vitamin D metabolites, with imaging selected according to tumor histology and the suspected mechanism. Management prioritizes individualized volume repletion, pharmacological suppression of osteoclast activity with denosumab or an intravenous bisphosphonate, current guidance conditionally favouring denosumab, and targeted oncological interventions. Ultimately, the onset of HAM in most thyroid malignancies remains an indicator of poor survival, necessitating a multidisciplinary approach to optimize both clinical outcomes and palliative quality of life. Thyroid-cancer-specific evidence remains limited and is derived largely from case reports and from extrapolation of general hypercalcemia-of-malignancy literature.

PMID 43037843
阅读全文 →
PubMedOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026-11-16

High fracture risk following discontinuation of anti-resorptive treatment due to medication-related osteonecrosis of the jaw in osteoporotic patients.

Courtier Sophie S, Balen Frederic F, Masson Maëva M, Constantin Arnaud A et al.

To our knowledge, the progression of osteoporosis and the associated fracture risk have never been studied in patients diagnosed with MRONJ secondary to ARDs for osteoporosis. Our study found a high frequency of fractures following MRONJ diagnosis and discontinuation of ARDs in these patients. Antiresorptive drugs (ARDs) are widely used to prevent osteoporotic fractures but can cause rare complications such as medication-related osteonecrosis of the jaw (MRONJ), often leading to discontinuation of therapy. This retrospective, monocentric, observational study aimed to study evolution of osteoporosis and fracture risk after MRONJ secondary to use of ARDs for osteoporosis. Patients diagnosed with MRONJ related to an ARD for osteoporosis between January 1, 2012, and August 1, 2022, were identified within the Maxillofacial Surgery department of Toulouse University Hospital, France. Data concerning fractures, comorbidities, MRONJ and osteoporosis treatments was collected by reviewing subjects' medical records. A total of 70 subjects (97% women) were included, with a mean age of 77 (± 8) years at the time of MRONJ, 60% having a history of osteoporotic fracture, 87% of taking bisphosphonates and 33% of taking denosumab. The cumulative duration of exposure to ARDs was 7.34 ± 4 years. ARDs had mostly been discontinued by the time of MRONJ (93%). Data on osteoporosis outcome was available for 55 patients, with a median follow-up time after MRONJ of 2.7 years (1.1 - 5.5). A new fracture was reported in 35% of patients (19/55). These were mostly severe fractures (65%), with a median fracture time of 2.8 years (1.4 - 4.5) after MRONJ and 2.1 years (1.4 - 4.5) after discontinuation of ARDs. Corticosteroid use was higher in the fracture group (42% vs 14%, p = 0.042), and follow-up duration was longer in the fracture group [4.5 years (1.9 - 8.6) vs 2.7 years (1.5 - 5.6), p = 0.08]. We found that 35% of patients experienced a fracture following MRONJ after discontinuation of ARDs, with a median delay of 2.1 years, suggesting that management of osteoporosis remains essential after the diagnosis of MRONJ.

PMID 43037675
阅读全文 →

注册免费账户还可查看另外 5681 篇文献

免费注册查看全部文献 →

了解更多denosumab